AIDX 20/20 Biolabs, Inc. Common Stock
Healthcare$0.98-18.67%ClosedMarket Cap: $5.5M
As of 2026-05-25
Valuation
P/E (TTM)
—
PEG
—
P/B
2.94
P/S
4.23
EV/EBITDA
-0.56
DCF Value
$-15,335.12
FCF Yield
-33.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
28.4%
Operating Margin
-266.7%
Net Margin
-320.9%
ROE
111.7%
ROA
-72.3%
ROIC
-102.2%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $353.4K | 17.8% | $-1.4M | $-2.1M | $— | — |
| FY null | $2.05B | 29.6% | $-3.33B | $-3.74B | $— | — |
| Q3 null | $418.0K | 34.7% | $-800.2K | $-825.5K | $— | — |
| Q4 null | $536.1K | 30.4% | $-1.2M | $-1.2M | $— | — |
| FY null | $1.8M | 20.6% | $-5.7M | $-5.6M | $— | — |
| Q3 null | $361.0K | 6.7% | $-1.9M | $-1.9M | $— | — |
| FY null | $1.4M | 7.7% | $-6.4M | $-6.4M | $— | — |
| Q2 null | $335.9K | 11.6% | $-1.8M | $-1.7M | $— | — |
| Q1 null | $419.4K | 0.4% | $-1.8M | $-2.0M | $— | — |
| FY null | $11.1M | 46.3% | $1.7M | $2.2M | $— | — |
| FY 2021 | $9.6M | 48.8% | $1.9M | $2.1M | $0.22 | — |
| FY 2020 | $2.3M | 37.6% | $-2.0M | $-2.0M | $-0.43 | — |